These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 18369325)

  • 1. Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy.
    Power AT; Bell JC
    Gene Ther; 2008 May; 15(10):772-9. PubMed ID: 18369325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential of tumour cells for delivering oncolytic viruses.
    Raykov Z; Rommelaere J
    Gene Ther; 2008 May; 15(10):704-10. PubMed ID: 18356816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth.
    Munguia A; Ota T; Miest T; Russell SJ
    Gene Ther; 2008 May; 15(10):797-806. PubMed ID: 18356812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelial progenitor cells as cellular vehicles to deliver oncolytic virus therapies to metastatic tumors: the "Trojan horse" approach.
    Deng W; Jia J
    Med Hypotheses; 2008; 70(4):842-4. PubMed ID: 17869010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery.
    Thorne SH; Contag CH
    Gene Ther; 2008 May; 15(10):753-8. PubMed ID: 18356814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy with radiation or cisplatin enhances the potency of Ad5/35 chimeric oncolytic adenovirus in a preclinical model of head and neck cancer.
    Ganesh S; Gonzalez-Edick M; Gibbons D; Ge Y; VanRoey M; Robinson M; Jooss K
    Cancer Gene Ther; 2009 May; 16(5):383-92. PubMed ID: 19011598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes?
    Stanford MM; Breitbach CJ; Bell JC; McFadden G
    Curr Opin Mol Ther; 2008 Feb; 10(1):32-7. PubMed ID: 18228179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The emergence of combinatorial strategies in the development of RNA oncolytic virus therapies.
    Nguyen TL; Tumilasci VF; Singhroy D; Arguello M; Hiscott J
    Cell Microbiol; 2009 Jun; 11(6):889-97. PubMed ID: 19388908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenovirus-mediated cancer gene therapy and virotherapy (Review).
    Fukazawa T; Matsuoka J; Yamatsuji T; Maeda Y; Durbin ML; Naomoto Y
    Int J Mol Med; 2010 Jan; 25(1):3-10. PubMed ID: 19956895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic viruses and histone deacetylase inhibitors--a multi-pronged strategy to target tumor cells.
    Nguyen TL; Wilson MG; Hiscott J
    Cytokine Growth Factor Rev; 2010; 21(2-3):153-9. PubMed ID: 20395162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers.
    Sinkovics JG; Horvath JC
    Arch Immunol Ther Exp (Warsz); 2008 Dec; 56 Suppl 1():3s-59s. PubMed ID: 19104757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploiting diversity: genetic approaches to creating highly potent and efficacious oncolytic viruses.
    Bauzon M; Hermiston TW
    Curr Opin Mol Ther; 2008 Aug; 10(4):350-5. PubMed ID: 18683099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ReVOLT: radiation-enhanced viral oncolytic therapy.
    Advani SJ; Mezhir JJ; Roizman B; Weichselbaum RR
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):637-46. PubMed ID: 17011442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Directing systemic oncolytic viral delivery to tumors via carrier cells.
    Nakashima H; Kaur B; Chiocca EA
    Cytokine Growth Factor Rev; 2010; 21(2-3):119-26. PubMed ID: 20226717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapy progress and prospects cancer: oncolytic viruses.
    Liu TC; Kirn D
    Gene Ther; 2008 Jun; 15(12):877-84. PubMed ID: 18418413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes.
    Pühler F; Willuda J; Puhlmann J; Mumberg D; Römer-Oberdörfer A; Beier R
    Gene Ther; 2008 Mar; 15(5):371-83. PubMed ID: 18200068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses.
    De Silva N; Atkins H; Kirn DH; Bell JC; Breitbach CJ
    Cytokine Growth Factor Rev; 2010; 21(2-3):135-41. PubMed ID: 20338801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models.
    Ganesh S; Gonzalez-Edick M; Gibbons D; Van Roey M; Jooss K
    Clin Cancer Res; 2008 Jun; 14(12):3933-41. PubMed ID: 18559615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Measles virus: a future therapeutic agent in oncology?].
    Touchefeu Y; Schick U; Harrington KJ
    Med Sci (Paris); 2012 Apr; 28(4):388-94. PubMed ID: 22549866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic vaccinia virus: from bedside to benchtop and back.
    Thorne SH
    Curr Opin Mol Ther; 2008 Aug; 10(4):387-92. PubMed ID: 18683104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.